QUESTION ASKED: What causes financial stress and what is its impact on health care utilization in patients with locally advanced head and neck cancer?
SUMMARY ANSWER: In our evaluation, 69% of patients used at least one cost-coping strategy within 6 months of treatment initiation. Medicaid, decreased wealth, higher total out-of-pocket costs, and high perceived social isolation were independently associated with increased utilization of cost-coping strategies, a proxy for patient-centered financial stress. Patients with high perceived social isolation were more likely to report nonadherence to supportive medications and to have greater numbers of missed clinical appointments.
WHAT WE DID:
We collected demographic data, as well as self-reported income, wealth, cost-coping strategies, out-of-pocket costs, supportive medication compliance, missed appointments, and length of inpatient admissions for a total period of 6 months in patients with locally advanced head and neck cancer in an academic center. Perceived social isolation was measured at baseline by assessing the availability of financial resources as well as loneliness and social support.
BIAS, CONFOUNDING FACTOR(S):
Several limitations of this study should be taken into consideration. The 6-month timeline inherently limits our ability to explore the long-term effects of costs on health care utilization and financial stress, along with important clinical outcomes, such as cancer-related and all-cause mortality. When planning this study, there were no validated measures to assess financial stress and we chose to adopt proxies, such as cost-coping strategies. A final consideration is that participants were recruited from a single academic institution, and the patient population or the out-of-pocket costs estimates may be associated with a specific location or practice pattern.
REAL-LIFE IMPLICATIONS:
Our findings shed light on the factors that lead to the adoption of strategies to cope with cancerrelated financial stress in patients with head and neck cancer. We found that having Medicaid as the insurance, decreased wealth, higher total out-of-pocket costs, and high perceived social isolation are independently associated with increased utilization of costcoping strategies. Herein, we emphasize the importance of social support at treatment initiation, a factor that is seldom assessed in clinical practice. High perceived social isolation was further associated with nonadherence to supportive medications and a greater number of missed clinical appointments over the period of 6 months post-treatment initiation. The strength of this paper relates to its prospective assessment over the treatment period and the inclusion of perceived social isolation as a measurable factor. To our knowledge, no studies have previously described the relationships between out-of-pocket costs, social isolation, compliance, and missed appointments, particularly in head and neck cancer. In the context of rising cancer care costs and oncology medical homes that strive for quality of care and patients' satisfaction, understanding the predictors of patient-centered financial stress before treatment initiation is mandatory if we are to design patient-level interventions.
INTRODUCTION
Despite dramatic advances in the management of head and neck cancer (HNC), the global incidence, morbidity, and mortality associated with HNC remain high. In the United States, HNC accounts for 3% of all malignancies, with 60,000 new cases annually. 1 In more than 75% of new cases, HNC is diagnosed at the locally advanced stage (LAHNC). 2 Whereas combined modality treatment, including chemotherapy, radiation therapy, and surgery, has been successful in achieving cure rates greater than 80% at 5 years, 3 the aggressive nature of these therapies create both acute and long-term toxicities that carry the potential to dismantle the lives of patients with cancer on multiple levels-including as it relates to financial well-being. Patient-centered financial stress is related to the nonreimbursed or out-of-pocket (OOP) costs, including direct medical and direct nonmedical costs on the patient. 4 These OOP costs constitute a large proportion of treatment expenses and may create negative effects on patients and their families.
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When considering indirect costs, as measured by lifetime lost wages, survivors of LAHNC have the highest risk of disability or of quitting work compared with patients with other cancers. 6 Herein, we aimed to prospectively describe the financial stress that patients experience and its predictors within the first 6 months of treatment at a tertiary university medical center.
METHODS

Participants
Patients at the University of Chicago Head and Neck Multidisciplinary Clinic with newly diagnosed LAHNC, including stage III, IVa, and IVb disease, were recruited for this prospective longitudinal study. All patients were treatment-naïve at the time of enrollment and were to receive concurrent chemoradiotherapy. Participants with Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from May 2013 to November 2014. Approval from the institutional review board at the University of Chicago and informed consent from each patient were obtained.
Measures
This prospective, observational study focused on the assessment of the costs of treatment for patients with LAHNC at the University of Chicago. At the time of enrollment, participants were asked to complete a survey regarding their social demographic characteristics, household income, OOP costs, and baseline levels of loneliness and social support. Wealth was defined as the "point-in-time stock of a household's financial assets, including both liquid forms such as money in a savings account, as well as illiquid forms such the net equity tied up in an owned home." 8(p250) We used the previously developed Duncan and Peterson's 8 income and wealth questionnaire.
Participants were then assessed once per month during follow-up oncology clinic visits for the next 6 months. Cost domains were collected from previously published questions that assessed various factors that are associated with financial stress. 9, 10 Patients were asked to report their monthly cancerrelated OOP costs, including insurance premiums; deductibles; direct medical costs, such as cash outlays for prescription and nonprescription medications, medical professional visits, hospital bills, nutritional services, physical therapy, speech therapy, alternative therapies, devices and equipment; and direct nonmedical costs, such as transportation, childcare, and other services. Financial burden for the individual patient with cancer was defined as the percentage of health-related spending, that is, total OOP costs, to household income, as previously reported. 11, 12 Financial burden of more than 10% is considered high. 11, 12 The Work Productivity and Activity Impairment
Questionnaire was used to estimate the lifetime lost wages as a result of reduced productivity as a measure of indirect costs. 13 The Work Productivity and Activity Impairment instrument is designed to fit the human capital method of estimating lifetime productivity costs per patient. 13, 14 Patient-centered financial stress was measured by assessing use of cost-coping strategies, 15 including selling possessions or property, using personal savings, borrowing money and taking credit card loans, and having family members work more hours to pay for costs associated with cancer during the study period. Health care utilization was measured by unexpected hospital admissions and scheduled outpatient oncology visits obtained from medical record chart review on the basis of a 6-month timeline per patient, beginning on the administered date of the initial survey and ending on the administered date of the 6-month survey. For medication adherence, we assessed for the number of days during which a patient took less supportive care medication of any type than prescribed-for example, analgesics and antiemetics-and whether this was a result of cost concerns. The chemotherapy these patients received was intravenous and clinically or hospital administered and thus achieved 100% compliance. Perceived social isolation (PSI) was measured at baseline and before any treatment by using the were defined as having high levels of PSI. Patients who were either lonely or who lacked social were classified as having moderate PSI, and those who were neither had low levels of PSI. 20 Statistical Analysis Univariable associations were analyzed using linear and logistic regression analyses. Multivariable models were adjusted for significant confounders, including age, sex, marital status, race/ethnicity, employment status, education level, insurance status, income, wealth, OOP costs, and indirect costs. Variables were selected for inclusion in multivariable models using the selection criterion of P , .10 in unadjusted analyses. Multivariable linear and logistic regression analyses were conducted to evaluate the independent effects of direct and indirect costs on use of cost-coping strategies, health care utilization, and supportive medication adherence. In final models, P , .05 was considered statistically significant. Demographic comparisons between patients with high PSI and low or moderate PSI were generated with t tests. All analyses were performed by using STATA/SE software (version 12.1; STATA, College Station, TX; Computing Resource Center, Santa Monica, CA).
RESULTS
Participants
Of 121 eligible patients during the recruitment period, 73 (60.3%) agreed to participate in the study. Nonresponders included those who declined to participate and those who initially agreed but did not complete the initial survey or revoked consent. Median age of participants was 60 years (range, 26 to 79 years). Most participants were non-Hispanic white (74%) and male (78.1%). Participant demographics are described in Table 1 . Seven patients (9.6%) were classified as having high PSI. Median monthly OOP was $805.93 (range, $6 to $10,156). Median indirect cost was $135,271.10 (range, $0 to $1,317,882). Summary of income, wealth, and costs can be found in Table 1 .
Cost-Coping Strategies as a Proxy for PatientCentered Financial Stress
To pay for OOP cancer-related expenses, 51 patients (69%) used at least one of the four cost-coping strategies during the 6-month study period. As seen in Fig 1, 45 patients (62%) used all or a portion of their savings, 31 (42%) borrowed money or used credit, 18 (25%) sold possessions or property, and 17 (23%) had family members work longer hours to pay for cancer-related costs.
Determinants of Cost-Coping Strategies Within 6 Months
Multivariable models were adjusted for significant confounders, including age, sex, marital status, race/ethnicity, employment status, education level, insurance status, income, wealth, total OOP costs, and indirect costs. Medicaid patients were more likely than privately insured patients to use cost-coping strategies (odds ratio, 42.3; P = .0042). Decreased wealth (P = .002) and higher total OOP costs (P = .003) were both independent predictors for greater use of coping strategies. Furthermore, patients with high PSI were more likely to use cost-coping strategies compared with those with moderate or low PSI (odds ratio, 11.5; P = .011). The results of multivariable regression analyses are described in Table 2 .
Health Care Utilization-Supportive Medication Compliance, Missed Appointments, and Length of Inpatient Admission
On average, there were 7 days of the 6 months in which patients were nonadherent to their medication regimen. The average number of no shows for outpatient appointments was 3.4 (standard deviation, 3.8), and the average length of unexpected hospital stays was 3.9 days (standard deviation, 7.4) over a period of 6 months. After stratifying patients by level of PSI, we found that participants with high PSI were more likely to be unemployed or disabled (P = .029) and divorced or widowed (P , .001) compared with other participants. Demographic comparisons are summarized in Appendix Table A1 (online  only) . Those with high PSI had significantly more days in which they were not adherent to their medication regimen because of cost concerns (P = .0278), and had significantly more no shows for appointments (P = .0077). There was a trend toward a positive association between PSI and unexpected length of stay in the hospital (P = .065). Results of two-sample t tests that compared supportive medication nonadherence and health care utilization are summarized in Table 3 .
DISCUSSION
In this analysis, we found that 69% of patients with LAHNC used at least one cost-coping strategy over the first 6 months of treatment. Having Medicaid, higher total OOP costs, lower wealth, and high PSI were independently associated with greater use of these cost-coping strategies. High PSI was also identified as an important social determinant of increased supportive medication nonadherence, no shows, and use of cost-coping strategies.
Compared with prior studies in the field, the strength of this work relates to its prospective assessment over the treatment period and the inclusion of PSI as a measurable factor. To our knowledge, no studies have previously described the relationships between OOP costs, PSI, and compliance in patients with LAHNC. In the context of rising cancer care costs, it will become increasingly important for patients with LAHNC, their families, and their providers to understand the predictors and effects of care- related expenses on health care utilization and financial well-being. Utilization of cost-coping mechanisms to defray cancer care costs has been well documented in other diseases. 21 Nipp et al 15 identified characteristics of patients who were at highest risk of utilizing cost-coping strategies as a result of breast or colorectal cancer-related financial stress. They found that 42% of patients borrowed money and credit card loans, 50% used personal savings, 18% sold possessions, and 15% had family members work longer hours; therefore, these lifestyle modifications may also be perceived as common effects of the disease and treatment of patients with LAHNC. When assessing the determinants of these cost-coping strategies, having Medicaid, higher total OOP costs, and lower wealth were independently associated with their greater use. Our findings are consistent with studies that have shown that those patients with lower income and those patients receiving Medicaid are more likely to suffer the consequences of financial stress. 19, 22, 23 Although OOP was associated with the use of cost-coping strategies in our analysis, it was not associated with adherence of supportive medications. This interesting finding suggests that coping strategies used by the patients in this sample may have mitigated nonadherence to supportive medications. In our analyses, PSI at baseline and before treatment has been identified as an important social determinant of using cost-coping strategies independent of other demographic characteristics, as well as a risk factor for suboptimal supportive medication adherence and missing appointments. This interesting fact may be related to measures adopted in this study, which assessed two domains of social isolation and support, namely, instrumental-material aid and financial assistance and support-and affective/loneliness-emotional support, advice, and guidance. Patients with high PSI were those who admitted to lack resources in both domains; therefore, these patients were mainly unemployed or divorced, both demographic groups that, in theory, are more likely to experience lack of financial-thus the greater use of cost-coping strategies-and social and emotional support, thus the greater number of missed appointments and less use of supportive medications. These results are important because social isolation is rarely assessed or documented in clinical practice. Nevertheless, we had a limited sample of seven patients classified as such, and further studies should be conducted not only to characterize this population, but also to understand what resources should be deployed. Several limitations of this study should be taken into consideration. The 6-month timeline inherently limits our ability to explore the long-term effects of cost on health care utilization and financial stress, along with important clinical outcomes, such as cancer-related and all-cause mortality. Although we had a 60% response rate in this longitudinal study, no data were collected for those who did not participate. When planning this study, there were no validated measures to assess financial stress 25 and we chose to adopt proxies, such as costcoping strategies. 15 Although comorbidities were not assessed, all patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. Another limitation is that we did not account for opportunity costs associated with leisure time and time loss for nonworking patients. A final consideration is that participants were recruited from a single academic institution, and the patient population or the OOP cost estimates may be associated with a specific location or practice pattern; however, collecting a convenience sample in a single institution offers a valuable and efficient opportunity to collect the health resource use and outcomes data for economic evaluations. 26 In conclusion, having high OOP costs, less wealth, Medicaid, and high baseline PSI are independently associated with financial stress within 6 months of LAHNC treatment. Patients with high PSI are also significantly more likely to take less medication than prescribed and miss more appointments compared with other patients. Our findings may help predict which patients are at greatest risk for adopting strategies to cope with cancer-related financial stress. In a resource-limited environment, it is important for clinicians before treatment initiation to identify patients who are at risk of suffering from financial stress. Financial advisors, patient navigators, and psychologists should be considered essential team members in modern, multidisciplinary HNC care. Interventions for minimizing financial stress, maximizing treatment compliance, and promoting effective health care utilization in patients with LAHNC are thus mandatory. These interventions may not only decrease the costs of cancer care to patients, but may also improve supportive medication adherence to treatment and ultimately lead to improvements in clinical outcomes. 
No. of Patients
